Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2

OncoImmunology

Volumn 4, Issue 8, 2015, Pages

  Rekers, Nicolle H ^a   Zegers, Catharina M L ^a   Germeraad, Wilfred T V ^b   Dubois, Ludwig ^a   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

cytotoxic T cells; ED B; immune response; immunotherapy

Indexed keywords

DARLEUKIN; FIBRONECTIN; INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CELL INFILTRATION; CELL PROLIFERATION; COLON CARCINOMA; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOGENICITY; KIDNEY CANCER; LEWIS CARCINOMA; METASTATIC MELANOMA; PHASE 1 CLINICAL TRIAL; RADIATION DOSE; SOLID TUMOR; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84940500691     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1021541     Document Type: Article

References (10)

1. S.Demaria, S.C.Formenti. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2012; 2:153; PMID:23112958; http://dx.doi.org/10.3389/fonc.2012.00153
2. P.Kaur, A.Asea. Radiation-induced effects and the immune system in cancer. Front Oncol 2012; 2:191; PMID:23251903; http://dx.doi.org/10.3389/fonc.2012.00191
3. D.V.Krysko, A.D.Garg, A.Kaczmarek, O.Krysko, P.Agostinis, P.Vandenabeele. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12:860-75; PMID:23151605; http://dx.doi.org/10.1038/nrc3380
4. D.R.Green, T.Ferguson, L.Zitvogel, G.Kroemer. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9:353-63; PMID:19365408; http://dx.doi.org/10.1038/nri2545
5. N.H.Rekers, E.G.Troost, C.M.Zegers, W.T.Germeraad, L.J.Dubois, P.Lambin. Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives. Cancer Radiother 2014; 18:391-5; PMID:25179250; http://dx.doi.org/10.1016/j.canrad.2014.06.012
6. S.A.Rosenberg. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014; 192:5451-8; PMID: 24907378; http://dx.doi.org/10.4049/jimmunol.1490019
7. T.List, D.Neri. Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol 2013; 5:29-45; PMID:23990735; http://dx.doi.org/10.2147/CPAA.S49231
8. C.M.Zegers, N.H.Rekers, D.H.Quaden, N.G.Lieuwes, A.Yaromina, W.T.Germeraad, L.Wieten, E.A.Biessen, L.Boon, D.Neri et al. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res 2015; 21(5):1151-60; PMID:25552483; http://dx.doi.org/10.1158/1078-0432.CCR-14-2676
9. M.A.Postow, M.K.Callahan, C.A.Barker, Y.Yamada, J.Yuan, S.Kitano, Z.Mu, T.Rasalan, M.Adamow, E.Ritter et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925-31; PMID:22397654; http://dx.doi.org/10.1056/NEJMoa1112824
10. S.Chouaib, Y.Messai, S.Couve, B.Escudier, M.Hasmim, M.Z.Noman. Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol 2012; 3:21; PMID:22566905; http://dx.doi.org/10.3389/fimmu.2012.00021